istock-635475308-1-
CIPhotos / iStockphoto.com
18 January 2018Americas

PTAB invalidates Johnson & Johnson cancer drug patent

The Patent Trial and Appeal Board (PTAB) has invalidated a Johnson & Johnson (J&J) patent covering its prostate cancer drug Zytiga (abiraterone acetate).

Argentum Pharmaceuticals, the generics company that had applied for an inter partes review (IPR) of the patent, was handed victory yesterday, January 17.

Argentum was granted its IPR petition for claims 1 to 20 of US patent number 8,822,438 in September 2016. The patent is called “Methods and compositions for treating cancer”.

Two articles and US patent number 5,604,213 were cited as prior art by Argentum in its petition.

The PTAB, in a final written decision, held that the claims were unpatentable over combinations of the articles and the patent.

In a press release, J&J said it was disappointed in, and strongly disagreed with, the decision.

“We are evaluating our options with respect to a request for rehearing and/or appeal to the US Court of Appeals for the Federal Circuit. We believe the ‘438 patent is valid and will continue to vigorously defend it,” said the release.

Jeffrey Gardner, CEO of Argentum, said: “We are pleased that the US Patent and Trademark Office has ruled in Argentum’s favour by holding all claims of the last remaining Orange Book patent for Zytiga to be obvious.”

In November, the PTAB granted Argentum’s petition for an IPR of a patent covering Valeant Pharmaceutical’s Jublia (efinaconazole topical solution 10%).

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories like this sent straight to your inbox.


More on this story

Big Pharma
16 May 2019   The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.
Biotechnology
20 July 2020   Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.
Americas
11 February 2021   A Johnson & Johnson unit has accused eye care product manufacturer Alcon of trade secrets theft, alleging that it had perpetrated “piracy of a nearly unfathomable scale” in ripping off a computer code.

More on this story

Big Pharma
16 May 2019   The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.
Biotechnology
20 July 2020   Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.
Americas
11 February 2021   A Johnson & Johnson unit has accused eye care product manufacturer Alcon of trade secrets theft, alleging that it had perpetrated “piracy of a nearly unfathomable scale” in ripping off a computer code.